Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Vitreoretinal Disease: Clinical Insights and Treatment Strategies
share announcement

Vitreoretinal Disease: Clinical Insights and Treatment Strategies

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 2544

Special Issue Editor

Prof. Dr. Makoto Inoue

E-Mail Website
Guest Editor
Department of Ophthalmology, Kyorin University School of Medicine, 6-20-2, Shinkawa, Mitaka, Tokyo 181-8611, Japan
Interests: vitreoretinal diseases; vitreoretinal surgery; vitrectomy; macular edema; retinal detachment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is dedicated to offering a comprehensive and cutting-edge overview of vitreoretinal diseases, their clinical presentations, and the latest advancements in diagnosis and treatment strategies. Vitreoretinal diseases encompass a diverse range of ocular conditions that affect the vitreous humor, retina, and surrounding structures, presenting significant challenges for both patients and ophthalmologists.

Within this collection, we explore the pathophysiology, epidemiology, and associated risk factors of various vitreoretinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy, retinal detachment, vitreomacular traction, and more. The authors share recent research findings and diagnostic modalities that facilitate early detection and precise diagnosis of these conditions.

Emphasizing innovative treatment approaches and surgical techniques, this Special Issue sheds light on strategies aimed at improving visual outcomes and overall patient management. Therapeutic interventions like intravitreal injections, laser photocoagulation, vitrectomy, and emerging pharmacological therapies are discussed, with insights into their efficacy and safety profiles.

Esteemed experts in the field contribute their knowledge and experience, providing valuable insights and evidence-based recommendations for clinical decision-making. This Special Issue serves as a valuable resource for ophthalmologists, optometrists, researchers, and healthcare professionals involved in the management of patients with vitreoretinal diseases.

By consolidating the latest advancements and best practices, the Special Issue seeks to enhance understanding, facilitate early diagnosis, and promote effective treatment of vitreoretinal diseases. Ultimately, these efforts contribute to improved patient outcomes and an enhanced quality of life.

Prof. Dr. Makoto Inoue
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vitreoretinal disease
  • age-related macular degeneration
  • diabetic retinopathy
  • retinal detachments
  • retinitis pig-mentosa
  • flashes and floaters
  • macular holes

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 1034 KiB  
Article
Nationwide Screening Practices for Tamoxifen Retinal Toxicity in South Korea: A Population-Based Cohort Study
by Seong Joon Ahn, Jiyeong Kim and Hyeon Yoon Kwon
J. Clin. Med. 2024, 13(8), 2167; https://doi.org/10.3390/jcm13082167 - 09 Apr 2024
Viewed by 295
Abstract
(1) Background/Objectives: To investigate the nationwide screening practices and trends in tamoxifen retinal toxicity (tamoxifen retinopathy) in South Korea using national health insurance claims data. (2) Methods: A total of 43,848 patients who started tamoxifen therapy between 2015 and 2020 and had no [...] Read more.
(1) Background/Objectives: To investigate the nationwide screening practices and trends in tamoxifen retinal toxicity (tamoxifen retinopathy) in South Korea using national health insurance claims data. (2) Methods: A total of 43,848 patients who started tamoxifen therapy between 2015 and 2020 and had no prior ophthalmic diseases or other conditions requiring screening for retinopathy were included. The annual numbers of tamoxifen users and new initiators of tamoxifen therapy were assessed. The screening examinations were separated into baseline (first ophthalmic examination after tamoxifen administration) and subsequent monitoring examinations. The timing and modalities for the baseline and subsequent monitoring examinations performed between 2015 and 2021 were assessed in tamoxifen users. (3) Results: The annual number of tamoxifen users increased over the study period from 54,056 in 2015 to 81,720 in 2021. The number of patients who underwent ophthalmic examination after tamoxifen administration was 8961 (20.4%). Baseline screening was performed in 6.5% of patients within 1 year of use, and subsequent monitoring was performed in 27.8% of patients who underwent baseline screening. Funduscopy or fundus photography was performed most commonly for baseline screening and subsequent monitoring (99.0% and 98.6%, respectively), while optical coherence tomography was performed only in 21.9% and 29.6% of baseline and monitoring examinations, respectively. The average number of monitoring examinations per year was 0.68 ± 0.45. Although the annual percentage of patients receiving a baseline examination within 1 year gradually increased over time, the percentage of those with subsequent monitoring performed within 1 year was similar over the study period. (4) Conclusions: Our finding, appropriate screening in a small proportion of patients receiving tamoxifen, suggests the need to promote awareness among healthcare professionals and develop a standardized approach for screening for tamoxifen retinopathy. Full article
(This article belongs to the Special Issue Vitreoretinal Disease: Clinical Insights and Treatment Strategies)
►▼ Show Figures

Figure 1

10 pages, 2751 KiB  
Article
Autosomal Dominant Retinitis Pigmentosa Secondary to TOPORS Mutations: A Report of a Novel Mutation and Clinical Findings
by Alen T. Eid, Kevin Toni Eid, James Vernon Odom, David Hinkle and Monique Leys
J. Clin. Med. 2024, 13(5), 1498; https://doi.org/10.3390/jcm13051498 - 05 Mar 2024
Viewed by 798
Abstract
Purpose: Mutations in Topoisomerase I–binding RS protein (TOPORS) have been previously documented and have been described to result in pathological autosomal dominant retinitis pigmentosa (adRP). In our study, we describe the various genotypes and clinical/phenotypic manifestations of TOPORS-related mutations of our unique patient [...] Read more.
Purpose: Mutations in Topoisomerase I–binding RS protein (TOPORS) have been previously documented and have been described to result in pathological autosomal dominant retinitis pigmentosa (adRP). In our study, we describe the various genotypes and clinical/phenotypic manifestations of TOPORS-related mutations of our unique patient population in Rural Appalachia. Methods: The medical records of 416 patients with inherited retinal disease at the West Virginia University Eye Institute who had undergone genetic testing between the years of 2015–2022 were reviewed. Patients found to have pathologic RP and mutations related to TOPORS were then analyzed. Results: In total, 7 patients (ages 12–70) were identified amongst three unique families. All patients were female in our study. The average follow-up period was 7.7 years. A mother (70 yr) and daughter (51 yr) had a novel heterozygous nonsense point mutation in TOPORS c.2431C > T, p.Gln811X (Exon 3) that led to premature termination of the desired protein resulting in early onset vision loss, cataract formation, and visual field restriction. The mother developed a full-thickness macular hole which was successfully repaired. Five other patients were found to have previously described TOPORS mutations. Visual field loss was progressive with age in both cohorts. Conclusions: Seven patients at our institution were identified to have mutations in TOPORS resulting in autosomal dominant retinitis pigmentosa. Two patients were found to have novel truncating mutations in the TOPORS gene resulting in profound night blindness and visual field loss, recurrent macular edema, and in one individual, epiretinal membrane formation leading to a macular hole which was able to be successfully repaired. Full article
(This article belongs to the Special Issue Vitreoretinal Disease: Clinical Insights and Treatment Strategies)
►▼ Show Figures

Figure 1

12 pages, 1228 KiB  
Article
Fixed Quarterly Dosing of Aflibercept after Loading Doses in Neovascular Age-Related Macular Degeneration in Chinese Eyes
by Daniel H. T. Wong and Kenneth K. W. Li
J. Clin. Med. 2024, 13(1), 145; https://doi.org/10.3390/jcm13010145 - 27 Dec 2023
Cited by 1 | Viewed by 683
Abstract
We aimed to investigate the success rate of planned fixed quarterly aflibercept injections after three loading doses (QDA3L) to achieve stability without recurrence in neovascular age-related macular degeneration (nAMD) at a tertiary eye centre. A retrospective study was conducted over five years (2017–2021) [...] Read more.
We aimed to investigate the success rate of planned fixed quarterly aflibercept injections after three loading doses (QDA3L) to achieve stability without recurrence in neovascular age-related macular degeneration (nAMD) at a tertiary eye centre. A retrospective study was conducted over five years (2017–2021) by including all consecutive cases of nAMD treated with three initial aflibercept injections four weeks apart, followed by planned injection appointments every 12 to 16 weeks starting from week 20. The primary endpoint was to determine the proportion of patients who maintained disease inactivity at week 52 and week 104. A total of 40 eyes of 40 patients were included. The overall mean age was 80.8, with a male preponderance. The overall success rate in our study population was 52.9% and 53.6% at week 52 and week 104, respectively. The fovea remained dry at 85.3% at week 52 and 82.1% at week 104, and 85.3% and 85.7% of subjects lost fewer than 15 ETDRS letters at week 52 and week 104, respectively. While this study does not suggest the superiority of this regimen, the success and failure rates obtained in our study can be used in the counselling process for this particular fixed treatment regimen for nAMD. Full article
(This article belongs to the Special Issue Vitreoretinal Disease: Clinical Insights and Treatment Strategies)
►▼ Show Figures

Figure 1

Other

Jump to: Research

8 pages, 217 KiB  
Brief Report
Prevalence and Associations of Epiretinal Membranes in an Elderly English Population: The Bridlington Eye Assessment Project
by Craig Wilde, Georgios D. Panos, Ali Pooschti, Hamish K. MacNab, Jonathan G. Hillman, Stephen A. Vernon and Winfried M. Amoaku
J. Clin. Med. 2024, 13(3), 739; https://doi.org/10.3390/jcm13030739 - 27 Jan 2024
Viewed by 477
Abstract
Purpose: To determine the prevalence and risk factors of epiretinal membranes (ERMs) in an adult English population. Methods: The Bridlington Eye Assessment Project is a population-based study of eye disease among residents aged 65 years or older. Comprehensive interviews and ophthalmic examinations were [...] Read more.
Purpose: To determine the prevalence and risk factors of epiretinal membranes (ERMs) in an adult English population. Methods: The Bridlington Eye Assessment Project is a population-based study of eye disease among residents aged 65 years or older. Comprehensive interviews and ophthalmic examinations were conducted to assess potential risk factors. Digital mydriatic nonstereoscopic 30° colour fundus photography (CFP) was performed. ERMs were classified as primary/idiopathic or secondary on the basis of findings from the ocular examination and the structured questionnaire. Logistic regression models were used to determine the independence of potential risk factors for idiopathic ERMs. Results: In a comprehensive screening of 3588 patients aged over 65, we identified an eye-based prevalence of ERMs of 4.26% and a subject-based prevalence of ERMs of 6.88%. The majority of these cases were idiopathic in nature (90.7%), while 9.3% were secondary ERMs; predominantly, there was a history of cataract surgery (43.5%). No significant correlation between idiopathic ERMs and factors such as age, gender, diabetes, hypertension, a history of stroke, or the presence of AMD was found. Conclusions: The prevalence of ERMs in an elderly English population and the proportion of idiopathic and secondary ERMs are similar to previous reports. However, in elderly patients aged over 65 years, age is not a risk factor for the presence of idiopathic ERMs. The presence of diabetes, hypertension, a history of stroke, and AMD of any grade was not associated with ERMs. Full article
(This article belongs to the Special Issue Vitreoretinal Disease: Clinical Insights and Treatment Strategies)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop